Valuation: Bonesupport Holding AB

Market Cap 15.32B 1.58B 1.39B 1.28B 1.18B 2.25B 150B 2.28B 5.96B 74.2B 5.95B 5.82B 256B P/E 2026 *
50.4x
P/E 2027 * 30.9x
Enterprise Value 14.71B 1.52B 1.33B 1.23B 1.14B 2.16B 144B 2.19B 5.72B 71.23B 5.71B 5.59B 246B EV / Sales 2026 *
9.82x
EV / Sales 2027 * 7.24x
Free-Float
85.24%
Yield 2026 *
0.62%
Yield 2027 * 0.93%

Last Transcript: Bonesupport Holding AB

1 week+9.57%
Current month+9.57%
1 month+3.62%
3 months+7.40%
6 months+24.22%
Current year+21.44%
1 week 18.47
Extreme 18.47
21.44
1 month 17.7
Extreme 17.7
21.54
3 years 9.52
Extreme 9.525
35.58
5 years 3.26
Extreme 3.255
35.58
Manager TitleAgeSince
Chief Executive Officer 49 2025-08-31
Director of Finance/CFO 63 2018-10-31
Chief Operating Officer 51 2021-11-30
Director TitleAgeSince
Director/Board Member 68 2009-12-31
Chairman 70 2016-12-14
Chairman 71 2019-05-13
Change 5-day change 1-year change 3-year change Capi.($)
-0.09%+9.57%-17.72%+96.29% 1.58B
+4.07%+8.45%+25.67%-2.34% 68.8B
-0.24%-3.13%+49.38%+223.97% 55.21B
+1.21%+42.20%+42.20%+42.20% 43.46B
+0.00%+8.04%-50.01%-53.56% 41.18B
-2.48%+13.91%+166.79%-32.89% 31.65B
-1.32%-4.79%+58.07%-25.22% 30.37B
+2.10%+4.14%+75.49%+90.19% 23.58B
-0.29%+9.11%+5.21%+187.11% 19.33B
-0.04%+3.85%+67.76%+135.89% 17.16B
Average +0.32%+4.29%+42.28%+66.16% 36.75B
Weighted average by Cap. +0.73%+4.19%+43.11%+54.93%

Financials

2026 *2027 *
Net sales 1.5B 155M 135M 125M 116M 220M 14.69B 223M 582M 7.25B 581M 569M 25.06B 1.98B 205M 180M 165M 153M 291M 19.48B 296M 772M 9.61B 770M 754M 33.22B
Net income 309M 31.96M 27.97M 25.78M 23.89M 45.36M 3.03B 46.09M 120M 1.5B 120M 117M 5.17B 508M 52.52M 45.96M 42.36M 39.26M 74.53M 4.98B 75.73M 198M 2.46B 197M 193M 8.5B
Net Debt -613M -63.43M -55.51M -51.15M -47.41M -90.01M -6.02B -91.46M -239M -2.97B -238M -233M -10.27B -948M -98.03M -85.79M -79.06M -73.28M -139M -9.3B -141M -369M -4.59B -368M -360M -15.87B
Logo Bonesupport Holding AB
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Employees
-
Date Price Change
26-07-07 €21.18 -0.09%
26-07-06 €21.20 +3.82%
26-07-03 €20.42 +2.36%
26-07-02 €19.95 +5.72%
26-07-01 €18.87 -2.38%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
232.60SEK
Average target price
371.83SEK
Spread / Average Target
+59.86%

Quarterly revenue - Rate of surprise